Table 1.
SN | Nucleic Acid | Gene/Target | Vector | Disease/Condition | Route of Delivery | Animal/Cell Line Used | Ref. |
---|---|---|---|---|---|---|---|
1 | mRNA | EPO | LNPs | - | IV | C57BL/6 mice | [35] |
2 | mRNA | Luciferase | LNPs | - | IP, IM, SC, IV, ID and ITr | BALB/c mice | [34] |
3 | mRNA | FXN | LNPs | Friedreich’s ataxia | ICV | BALB/c mice | [36] |
4 | mRNA | Luciferase and hEPO | LNPs | - | IV | CD-1 mice, rats, cynomolgus monkeys | [37] |
5 | mRNA | pRM and E | LNPs | Zika | IM | AG129 mice | [41] |
6 | siRNA and mRNA | Factor VII and luciferase | LNPs | - | IV | C57BL/6 mice | [53] |
7 | siRNA | PCSK9 | LNPs | Elevated LDL-Cholesterol | IV | C57BL/6 mice and monkeys | [56] |
8 | mRNA | PCSK9 | LNPs | Elevated LDL-Cholesterol | IV | BALB/c mice | [72] |
9 | G3139-GAP | Bcl-2 | LNPs | Lung cancer | IV | BALB/c mice | [74] |
10 | mRNA | Luciferase | hPBAEs NPs | - | Inhalation | C57BL/6 mice | [88] |
11 | mRNA | EPO | PACE NPs | - | IV | BALB/c mice | [89] |
12 | siRNA | CIITA | PACE NPs | Tissue transplantation | Incubation | SCID/beige mice | [91] |
13 | siRNA | Nogo-B | PACE NPs | Hepatic fibrosis and alcoholic liver disease | Spleen | C57BL/6 mice | [92] |
14 | ASO | Human telomerase | Chitosan-coated PLGA NPs | Lung cancer | Cellular uptake | A549 cancer cell line | [97] |
15 | ASO | miR-21 | PACE NPs | Glioblastoma | CED | Fischer 344 rats | [103] |
16 | siRNA | PLK-1 | EGF antibody Anti-HB -LNPs | Triple negative breast cancer | IV | BALB/c mice | [110] |
17 | siRNA | ApoB | PBAVE NPs | - | IV | ICR mice | [132] |
18 | ZFN mRNA | SFTB | Chitosan-coated PLGA NPs | Lung disease | ITh | SP-B transgenic mice | [140] |
19 | ZFN mRNA | TTR and PCSK9 | LNPs | Elevated LDL-Cholesterol and amyloidosis | IV | CD-1 mice | [141] |
20 | Cas9 and sgRNA | EGFP | PEI coated DNA nanoclew | Osteosarcoma | IT | Nude mice | [144] |
21 | Cas9 and sgRNA | PCSK 9 and HBV | LLNs | Elevated LDL-Cholesterol and Hepatitis B | IV | C57BL/6 mice | [142] |
Abbreviations: EPO, erythropoietin; LNPs, lipid nanoparticles; FXN, frataxin; FVII, protein Factor VII; PCSK9, proprotein convertase subtilisin/kexin type 9; bcl-2, B-cell lymphoma 2; prM, pre-membrane protein; E, envelope protein; CIITA, class II transactivator; Nogo-B, Nogo-B gene, a part of Nogo/Reticulon-4B family; hPBAEs, hyper branched poly-β-amino esters; PACE, poly(amino-co-ester); PLGA, poly(lactic-co-glycolic acid); miR-21, microRNA-21; PLK-1, polo-kinase 1; ApoB, apolipoprotein; PBAVE; poly(butyl amino vinyl ether) polymer; PEI, polyethylenimine; TTR, transthyretin; EGFP, epidermal growth factor protein; SFTB, surfactant B gene encoding for surfactant B protein; sgRNA, single guide RNA; HBV, hepatitis B virus; IV, intravenous; IP, intraperitoneal; IM, intramuscular; SC, subcutaneous; ID, intradermal; ITr, intratracheal; ICV, intracereboventicular; IT, intratumoral; ITh, intrathecal; CED, convection enhanced delivery.